The following studies were focused on prostate cancer, particularly the most clinically vexing aspect of the disease in which a ‘castration-resistant’ tumor continues to grow even though the patient receives treatments to lower the tumor-promoting actions of androgens (testosterone) acting through the androgen receptor (AR). Here, AR is linked to prostate carcinoma.